Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT ID: NCT05016882
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
698 participants
INTERVENTIONAL
2021-08-31
2025-03-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499. The 2 medicines may work better together than on their own.
The study will also look at a combination of semaglutide and another weight-loss medicine called NNC0174-0833, which may be another treatment option for NASH.
Each week, participants will get 2 injections. These could be 2 of the 3 medicines OR 1 of the medicines and a placebo OR 2 placebo injections. Which treatment participants get is decided by chance. A placebo is a dummy medicine which looks like the real medicine but doesn't contain any active medicine.
The study will last for about 19 months. Participants will have 14 clinic visits and 9 phone calls with the study doctor.
Participants will have 1 or 2 liver biopsies (tiny pieces of liver tissue) - one at the start (if participants have not had a biopsy recently) and one at the end of the study treatment.
Women: Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
NCT02970942
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
NCT03987451
Semaglutide in Nonalcoholic Fatty Liver Disease
NCT05813249
Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis
NCT01237119
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NNC0194-0499 7.5 mg + semaglutide 2.4 mg
Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
NNC0194 0499 50 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
Semaglutide 3 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg
Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
Placebo (NNC0194-0499)
Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
Semaglutide placebo
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
NNC0194-0499 15 mg + semaglutide 2.4 mg
Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
NNC0194 0499 50 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
Semaglutide 3 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg
Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
Placebo (NNC0194-0499)
Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
Semaglutide placebo
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
NNC0194-0499 30 mg + semaglutide 2.4 mg
Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
NNC0194 0499 50 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
NNC0194-0499 30 mg + semaglutide placebo 2.4 mg
Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
NNC0194 0499 50 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
Semaglutide placebo
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg
Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
Placebo (NNC0194-0499)
Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
Semaglutide 3 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg
Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
Placebo (NNC0194-0499)
Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
Semaglutide placebo
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
NNC0174-0833 2.4 mg + semaglutide 2.4 mg
Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
Semaglutide 3 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
NNC0174 0833 10 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg
Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
Semaglutide placebo
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
NNC0174 0833 placebo
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NNC0194 0499 50 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
Placebo (NNC0194-0499)
Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
Semaglutide 3 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
Semaglutide placebo
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
NNC0174 0833 10 mg/mL
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
NNC0174 0833 placebo
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histological evidence of NASH based on a central pathologist evaluation of the baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to Visit 1.
* Histological evidence of fibrosis stage 2, 3 or 4 according to the NASH CRN classification based on a central pathologist evaluation of the baseline liver biopsy.
* Histological non-alcoholic fatty liver disease (NAFLD) activity score (NAS) greater than or equal to 4 for subjects with F2/F3 or greater than or equal to 3 for subjects with F4 based on a central pathologist evaluation of the baseline liver biopsy. All subjects must have a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning.
Exclusion Criteria
* Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).
* Presence or history of ascites more than grade 1, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at V2A.
* For subjects with F4, presence or history of gastro-oesophageal varices more than or equal to grade 2 at V3. An oesophagogastroduodenoscopy performed no more than 52 weeks prior to V3 must be available at V3.
* Known or suspected excessive consumption of alcohol (more than 20 g/day for women or more than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).
* Treatment with vitamin E (at doses more than or equal to 800 IU/day) or pioglitazone or medications approved for the treatment of NASH which has not been at a stable dose in the opinion of the investigator in the period from 90 days prior to V2A. In addition, for subjects with a historical liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until V2A.
* Treatment with GLP-1 RAs within 90 days prior to V2A. Subjects with a historical liver biopsy taken more than 90 days prior to V2A are excluded if they receive treatment with GLP-1 RAs from time of biopsy until V2A.
* Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to V2A. In addition, for subjects with a historical liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until V2A.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Transparency (dept. 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North AL Health Res, LLC
Huntsville, Alabama, United States
The Institute for Liver Health
Chandler, Arizona, United States
Inst-Liver Hlth dba AZ Liver H
Peoria, Arizona, United States
Del Sol Research Management, LLC
Tucson, Arizona, United States
Hope Clinical Research
Canoga Park, California, United States
UCSD NAFLD Research Center
La Jolla, California, United States
OM Research LLC
Lancaster, California, United States
Digestive Hlth Res of SoCa
Long Beach, California, United States
Stanford Medicine
Redwood City, California, United States
UC Davis Hlth -Midtwn Ambu Cen
Sacramento, California, United States
Peak Gastro Assoc-Col Springs
Colorado Springs, Colorado, United States
Hartford Hsptl_Hartford
Hartford, Connecticut, United States
Integrity Clinical Research, LLC
Doral, Florida, United States
Miguel Rebollar PA
Hialeah, Florida, United States
Nature Coast Clinical Research_Inverness
Inverness, Florida, United States
UF Hlth Jacksonville
Jacksonville, Florida, United States
Florida Research Institute, LLC
Lakewood Rch, Florida, United States
ClinCloud,LLC
Maitland, Florida, United States
Optimus U, Corp
Miami, Florida, United States
Univ of Miami/Schiff Ctr
Miami, Florida, United States
Covenant Metabolic Specialists LLC
University Park, Florida, United States
ClinCloud, LLC
Viera E., Florida, United States
Florida Medical Clinic Orlando Health
Zephyrhills, Florida, United States
Florida Medical Clinic, LLC
Zephyrhills, Florida, United States
Piedmont Healthcare
Atlanta, Georgia, United States
Digestive Healthcare of Georgia
Atlanta, Georgia, United States
Gastroenterology Assoc_ CGA
Macon, Georgia, United States
Gastroint Spec of Georgia
Marietta, Georgia, United States
EBGS Clinical Research Center, LLC
Snellville, Georgia, United States
Grand Teton Gastroenterology
Idaho Falls, Idaho, United States
Digestive Research Alliance of Michiana
South Bend, Indiana, United States
University Of Kansas Hospital
Kansas City, Kansas, United States
Kansas Medical Clinic, PA
Topeka, Kansas, United States
Tandem Clinical Research - Houma
Houma, Louisiana, United States
Tandem Clinical Research
Marrero, Louisiana, United States
Tandem Clinical Research - Metairie
Metairie, Louisiana, United States
Louisiana Research Center, LLC
Shreveport, Louisiana, United States
Mercy Medical Center, GI Research
Baltimore, Maryland, United States
Walter Reed Nat Mil Md Ctr
Bethesda, Maryland, United States
Henry Ford Hospital_Detroit
Detroit, Michigan, United States
Kansas City Research Institute
Kansas City, Missouri, United States
Univ of Nebraska Medical CTR
Omaha, Nebraska, United States
AIG Digestive Disease Research
Florham Park, New Jersey, United States
NYU Grossman School of Med
New York, New York, United States
Weill Cornell Med Coll-NYPH
New York, New York, United States
Univ Hosp Cleveland Med Ctr
Cleveland, Ohio, United States
Ohio State Univ Wexner Med Ctr
Columbus, Ohio, United States
DSI Research,LLC
Springboro, Ohio, United States
Geisinger Clinic
Danville, Pennsylvania, United States
Pennsylvania State University
Hershey, Pennsylvania, United States
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
UPMC Center for Liver Diseases
Pittsburgh, Pennsylvania, United States
UPMC_Center for Liver Care
Pittsburgh, Pennsylvania, United States
Digestive Health Res-TSMC
Hermitage, Tennessee, United States
Quality Medical Research
Nashville, Tennessee, United States
Texas Clin Res Inst, LLC
Arlington, Texas, United States
Liver Ins@ Mthdist DTX Med Cen
Dallas, Texas, United States
Centex Studies, Inc.
Houston, Texas, United States
Amir Ali Hassan, MD, PA
Houston, Texas, United States
Texas Diabetes &Endocrinology
Round Rock, Texas, United States
Amer. Rrsch Corp-TX Liver Inst
San Antonio, Texas, United States
Olympus Clinical Research
Sugar Land, Texas, United States
Impact Research
Waco, Texas, United States
Digestive Hlth Res of N Texas
Wichita Falls, Texas, United States
Inova Fairfax Medical Campus
Falls Church, Virginia, United States
Bon Secours Richmond Community Hospital LLC
Richmond, Virginia, United States
Gastroent Consult of SW VA
Roanoke, Virginia, United States
Swedish med ctr org trans-lvr ctr
Seattle, Washington, United States
Liver Institute NW
Seattle, Washington, United States
Genesis Research Services
Broadmeadow, New South Wales, Australia
St Vincent's Hospital
Darlinghurst, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Adelaide Hospital - Hepatology- 5E291
Adelaide, South Australia, Australia
Monash Health Department of Gastroenterology
Clayton, Victoria, Australia
St Vincent's Hospital (Melbourne)
Fitzroy, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
The Alfred Centre - Gastroenterology
Melbourne, Victoria, Australia
Fiona Stanley Hospital - Hepatology
Murdoch, Western Australia, Australia
CUB Hôpital Erasme_Brussels_0
Brussels, , Belgium
Cliniques Universitaires Saint-Luc - Serv. Hépato-gastroentérology
Brussels, , Belgium
UZA
Edegem, , Belgium
UZ Gent - Department Gastro-enterology
Ghent, , Belgium
MHAT - UniHospital OOD
Panagyurishte, , Bulgaria
MHAT Med Line Clinic
Plovdiv, , Bulgaria
"Acibadem City Clinic UMHAT Tokuda"
Sofia, , Bulgaria
DCC Aleksandrovska EOOD
Sofia, , Bulgaria
UMHAT "Sv. Ivan Rilski", Clinic of Gastroenterology
Sofia, , Bulgaria
Medical Center Vertebra OOD
Sofia, , Bulgaria
"UMHAT "Tsaritsa Yoanna-ISUL"" EAD, Gastroenterology clinic
Sofia, , Bulgaria
"DCC XX - Sofia" EOOD
Sofia, , Bulgaria
University of Calgary Liver Unit-(HMRC)
Calgary, Alberta, Canada
GI Research Inst Foundation
Vancouver, British Columbia, Canada
QE II Health Sciences Centre
Halifax, Nova Scotia, Canada
LMC Manna Research Inc. (London)
London, Ontario, Canada
Toronto Liver Centre
Toronto, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Ctr de Med Metab de Lanaudiere
Terrebonne, Quebec, Canada
Krajská nemocice Liberec, a.s
Liberec, , Czechia
Fakultni nemocnice Plzen - Lochotin
Pilsen, , Czechia
Vseobecna Fakultni nemocnice v Praze
Prague, , Czechia
Hvidovre Hospital - Gastroenheden
Hvidovre, , Denmark
Abdominal Center K, Research Unit
København NV, , Denmark
Odense University Hospital
Odense C, , Denmark
Centre Hospitalier Universitaire D'Angers-1
Angers, , France
Ap-Hp-Hopital Beaujon
Clichy, , France
Centre Hospitalier Universitaire de Lille-Hopital Claude Huriez
Lille, , France
Hospices Civils de Lyon-Hopital de La Croix Rousse
Lyon, , France
Centre Hospitalier Universitaire de Nice-Hopital de L'Archet 2
Nice, , France
Aphp-Hopital La Pitie Salpetriere-4
Paris, , France
Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-1
Saint-Herblain, , France
Centre de Recherche Clinique Portes Du Sud
Vénissieux, , France
Klinik für Endokrinologie, Diabetologie und Stoffwechsel
Essen, , Germany
Uniklinik Schleswig-Holstein - Medizinischen Klinik I am Campus Lübeck
Lübeck, , Germany
Universitätsklinikum Schleswig-Holstein
Lübeck, , Germany
Universitätsmedizin der JGU Mainz - Hepatologie
Mainz, , Germany
Uniklinik Tübingen - Innere Medizin I
Tübingen, , Germany
Universitätsklinikum Würzburg - Zentrum für Innere Medizin (ZIM)
Würzburg, , Germany
Universitätsklinikum Würzburg, ZIM
Würzburg, , Germany
Gen Hospital of Athens Ippokrateio,B' Uni Clinic of Inte Med
Athens, , Greece
Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter
Athens, , Greece
Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter
Athens, , Greece
General Hospital of Athens "LAIKO"
Goudi, Athens, , Greece
"AHEPA" University Hospital of Thessaloniki
Thessaloniki, , Greece
General Hospital of Thessaloniki "Ippokrateio"
Thessaloniki, , Greece
Yashoda Hospital
Secunderabad, Andhra Pradesh, India
Surat Institute of Digestive Science
Surat, Gujarat, India
BAPS Pramukh Swami Hospital
Surat, Gujarat, India
Medanta - The Medicity Multi-Speciality Hospital, Gurugram
Gurugram, Haryana, India
Kasturba Medical College Hospitals (KMC Hospitals), Mangalore
Mangalore, Karnataka, India
KLES & Prabhakar Kore Hospital and Research Centre
Belagavi, Karnatka, India
Gleneagles Hospital, Super-speciality and Transplant Centre, Parel
Mumbai, Maharashtra, India
Seth GS medical college and KEM Hospital
Mumbai, Maharashtra, India
Midas Multispeciality Hospital
Nagpur, Maharashtra, India
Institute of liver and Biliary Sciences
Ghitorni, New Delhi, India
All India Institute of medical Sciences
New Dehli, New Delhi, India
Fortis Heart Institute and Multispeciality Hospital
Chandigarh,, Punjab, India
Post Graduate Institute of Medical Education & Research_Chandigarh
Chandigarh, Punjab, India
Dayanand Medical College & Hospital
Ludhiana, Punjab, India
S.R.Kalla Memorial Gastro & General Hospital
Jaipur, Rajasthan, India
SMS Medical College & Hospital
Jaipur, Rajasthan, India
Osmania General Hospital
Hyderabad, Telangana, India
Dr P V Rao - Diabetes Research Centre
Hyderabad, Telangana, India
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
Ancona, , Italy
Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
Bergamo, , Italy
Azieda Ospedaliero-Universitaria, Policlinico S. Orsola-Malp
Bologna, , Italy
AOU Careggi Padiglione 16 San Luca, 3° piano
Florence, , Italy
Azienda Ospedaliera di Padova Clin.Med.3
Padua, , Italy
AOU Pisana Stabilimento di Cisanello EDIFICIO 6, Piano 5
Pisa, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCS
Roma, , Italy
Policlinico Università Campus Biomedico di Roma
Rome, , Italy
Chiba University Hospital_Chiba-shi, Chiba
Chiba-shi, Chiba, , Japan
Fukui-ken Saiseikai Hospital, Internal Medicine
Fukui-shi, Fukui, , Japan
Hamamatsu University Hospital
Hamamatsu-shi, Shizuoka, , Japan
JA Hiroshima General Hospital_Gastroenterology and Hepatology
Hatsukaichi-shi, Hiroshima, , Japan
University Hospital Kyoto Prefectual University of Medicine
Kamigyo-ku, Kyoto, , Japan
St. Marianna University School of Medicine Hospital
Kawasaki-shi, Kanagawa, , Japan
Kumamoto Shinto General Hospital_Liver・Gastroenterology
Kumamoto-shi, Kumamoto, , Japan
Toranomon Hospital, Hepatology
Minato-ku, Tokyo, , Japan
Kawasaki Medical School General Medical Center_Internal Medicine
Okayama-shi, Okayama, , Japan
Saga University Hospital_Liver Center
Saga-shi, Saga, , Japan
Sendai Kousei Hospital
Sendai-shi, Miyagi, , Japan
Saiseikai Suita Hospital, Gastroenterology
Suita-shi, Osaka, , Japan
Ehime University Hospital_Department of Gastro.& Metabo.
Toon-shi, Ehime, , Japan
Ehime University Hospital
Toon-shi, Ehime, , Japan
Saiseikai Wakayama Hospital_Gastroenterology
Wakayama-shi, Wakayama, , Japan
Saiseikai Wakayama Hospital
Wakayama-shi, Wakayama, , Japan
Yokohama City University Hospital, Gastrointestinal Medicine
Yokohama-shi, Kanagawa, , Japan
Hospital Universiti Sains Malaysia
Kota Bharu, Kelantan, Malaysia
University Malaya Medical Centre
Lembah Pantai, Kuala Lumpur, Malaysia
Hospital Selayang
Batu Caves, , Malaysia
ID Clinic Arkadiusz Pisula
Myslowice, Lesser Poland Voivodeship, Poland
Spolka Lekarzy Intercor Sp. z o.o.
Bydgoszcz, , Poland
Clinical Medical Research Korfantego - Ambulatoryjna Opieka
Katowice, , Poland
Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibińskiego Śl
Katowice, , Poland
"LANDA" Katarzyna Agata Landa
Krakow, , Poland
Krakowskie Centrum Medyczne Sp. z o.o.
Krakow, , Poland
Centrum Medyczne Medyk Sp. z o.o.
Rzeszów, , Poland
EMC Instytut Medyczny S.A.
Wroclaw, , Poland
Centrum Badan Klinicznych
Wroclaw, , Poland
FutureMeds Sp. z o.o.
Wroclaw, , Poland
Velocity Nova Sp. z o.o.
Staszów, Świętokrzyskie Voivodeship, Poland
Unidade Local De Saude De Matosinhos E.P.E.
Senhora Da Hora, Matosinhos, Matosinhos, Portugal
Unidade Local De Saude De Santa Maria E.P.E.
Lisbon, , Portugal
Hospital Luz Arrabida, S.A.
Vila Nova de Gaia, , Portugal
FDI Clinical Research
San Juan, , Puerto Rico
Volosevich First City Clinical Hospital
Arkhangelsk, , Russia
City Hospital #5
Barnaul, , Russia
Limited Liability Company "Alliance Biomedical Ural Group"
Izhevsk, , Russia
Kazan Federal University
Kazan', , Russia
LLC "Clinic of Aesthetic Medicine & Laser Technologies"
Kazan', , Russia
Limited Liability Company "Polyclinica № 1"
Moscow, , Russia
Friendship University of Russia
Moscow, , Russia
FSBI 'I.I. Dedov National Medical Research Center of Endocrinology' of the MH of Russia
Moscow, , Russia
Setchenov First Moscow State Medical University
Moscow, , Russia
PHI "Central Clinical Hospital RZD- Medicine"
Moscow, , Russia
Pirogov Russian National Research Medical University MoH
Moscow, , Russia
LLC RC Medical
Novosibirsk, , Russia
RIIPM - branch of ICG SB of RAS
Novosibirsk, , Russia
Limited Law Company "Healthy Family" Medicine Center"
Novosibirsk, , Russia
LLC "Clinical diagnostic center Ultramed"
Omsk, , Russia
BHI of Omsk Region "City Hospital № 3"
Omsk, , Russia
Penza Regional Clinical Hospital named after N.N. Burdenko
Penza, , Russia
Joint Stock Company "Polyclinic Complex"
Saint Petersburg, , Russia
SPb SBHI City Outpatient clinic #109
Saint Petersburg, , Russia
Limited Liability Company "Clinic" MEDINEF "
Saint Petersburg, , Russia
Limited Liability Company "Energiya Zdoroviya"
Saint Petersburg, , Russia
X Seven Clinical Research Limited Liability Company
Saint Petersburg, , Russia
SPb SBHI City polyclinic #117
Saint Petersburg, , Russia
North-Western State Medical Univer. based on Med-Prof Center
Saint Petersburg, , Russia
Medical Research Institute LLC
Saint Petersburg, , Russia
Limited Liability Company "Research Center Eco-safety"
Saint Petersburg, , Russia
Private medical institution "Euromedservice"
Saint Petersburg, , Russia
Consultative & Diagnostic Center with a Outpatient Hospital
Saint Petersburg, , Russia
Siberian State Medical University
Tomsk, , Russia
Ulianovsk Regional Clinical Hospital
Ulyanovsk, , Russia
Joint Stock Company "Medical technologies"
Yekaterinburg, , Russia
Polyclinic #2 in Yoshkar-Ola
Yoshkar-Ola, , Russia
National University Hospital_Tahir Building
Singapore, , Singapore
National University Hospital_TBD
Singapore, , Singapore
Singapore General Hospital
Singapore, , Singapore
Changi General Hospital
Singapore, , Singapore
Korea University Ansan Hospital
Ansan, Gyeonggi-do, South Korea
Kyungpook National University Hospital
Daegu, , South Korea
Yeungnam Univ. Medical Center
Daegu, , South Korea
Keimyung University Dongsan Hospital
Daegu, , South Korea
Wonju Severance Christian Hospital
Gangwon-do, , South Korea
SoonChunHyang University Hospital Bucheon
Gyeonggi-do, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Chung-Ang University Hospital
Seoul, , South Korea
SMG-SNU Boramae Medical Center
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Complejo Hospitalario de Pontevedra - Hospital de Montecelo
Pontevedra, Galicia, Spain
Hospital Vall d'Hebron
Barcelona, , Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, , Spain
Hospital Universitario Marqués de Valdecilla
Santander, , Spain
Hospital Virgen del Rocío
Seville, , Spain
Hospital Clínico de Valladolid
Valladolid, , Spain
Ditmanson Medical Foundation Chia-Yi Christian Hospital
Chiayi City, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
National Cheng Kung University Hospital
Tainan, , Taiwan
National Taiwan University Hospital_main
Taipei, , Taiwan
Hacettepe Universitesi Tıp Fakültesi- Gastroenteroloji
Ankara, , Turkey (Türkiye)
Gazi University Medical Faculty
Ankara, , Turkey (Türkiye)
Gaziantep Üniversitesi Hastanesi
Gaziantep, , Turkey (Türkiye)
Bezmialem Vakıf Üniversitesi Hastanesi-Gastroenteroloji
Istanbul, , Turkey (Türkiye)
Cerrahpasa Kardiyoloji Enstitüsü
Istanbul, , Turkey (Türkiye)
Marmara Univ. Pendik Gastroenterology
Istanbul, , Turkey (Türkiye)
Kocaeli Universitesi Tıp Fakültesi Gastroenteroloji ve Hepat
Kocaeli, , Turkey (Türkiye)
Recep Tayyip Erdoğan Üniversitesi EAH-Endokrinoloji
Rize, , Turkey (Türkiye)
Adana Şehir Eğitim ve Araştırma Hastanesi
Yüreğir/Adana, , Turkey (Türkiye)
Queen Elizabeth Hospital, Birmingham
Birmingham, , United Kingdom
Royal Devon & Exeter NHS Foundation Trust
Exeter, , United Kingdom
Imperial College London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1255-5551
Identifier Type: OTHER
Identifier Source: secondary_id
2020-003566-39
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
NN9500-4656
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.